The importance of sign and symptoms assessment in patients with metastatic renal cell carcinoma: implications for cytoreductive nephrectomy

by A. Larcher, G. Fallara, G. Rosiello, G. Basile, C. Re, G. Baiamonte, S. Agnesi, D. Cignoli, G. Colandrea, A. Briganti, R. Bertini, A. Salonia, F. Montorsi, U. Capitanio
Published 2020-10-01

Pathological features and predictors of oncologic outcomes in patients with small renal masses

by R. Bertini, G. Rosiello, F. Muttin, G. Baiamonte, C. Re, S. Agnesi, C. Bravi, M. Bandini, G. Basile, D. Cignoli, A. Briganti, A. Salonia, F. Montorsi, U. Capitanio, A. Larcher
Published 2020-10-01

Is whenever feasible-strategy for partial nephrectomy invariably justified? the impact of clinical tumour size on postoperative renal function

by G. Fallara, A. Larcher, G. Rosiello, G. Basile, D. Cignoli, G. Colandrea, A. Martini, W. Cazzaniga, C.A. Bravi, M. Bandini, G. Baiamonte, A. Briganti, A. Salonia, R. Bertini, F. Montorsi, U. Capitanio
Published 2020-10-01

Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy

by V. Cucchiara, D. Lazarevic, D. Cittaro, M. Zoccolillo, M. Bianchi, N. Longo, S. Scuderi, F. Barletta, A. Martini, E. Mazzone, G. Basile, G.O. Cirulli, D. Cignoli, M. Tutolo, N. Fossati, G. Gandaglia, V. Mirone, F. Montorsi, G. Tonon, A. Briganti
Published 2020-10-01

The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE...

by D. Cignoli, A. Martini, J.P. Sfakianos, G. Gandaglia, N. Fossati, A. Salonia, F. Barletta, S. Scuderi, D. Robesti, C.A. Bravi, E. Mazzone, G. Rosiello, G. Fallara, L. Nocera, G.O. Cirulli, A. Stabile, A. Briganti, F. Montorsi, W.K. Oh, E.D. Gallagher, M.D. Galsky
Published 2020-10-01

The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer

by G.O. Cirulli, A. Stabile, G. Gandaglia, N. Fossati, C. Orczyc, F. Giganti, S. Scuderi, V. Cucchiara, D. Cignoli, E. Zaffuto, F. Barletta, F. Pellegrino, E. Vecchio, M. Moschini, N. Cathala, P. Macek, H.U. Ahmed, M. Emberton, X. Cathelineau, A. Briganti, F. Montorsi, R.Sanchez Salas, C.M. Moore
Published 2020-10-01

Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database

by G. Sorce, A. Martini, J. Pfail, U.G. Falgario, N. Waingankar, G. Gandaglia, N. Fossati, G. Fallara, F. Barletta, S. Scuderi, D. Robesti, D. Cannoletta, D. Cignoli, G. Basile, L. Nocera, G. Rosiello, E. Mazzone, C.A. Bravi, A. Necchi, F. Montorsi, A. Briganti, M.D. Galsky, J.P. Sfakianos
Published 2020-10-01

Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series

by E. Mazzone, A. Stabile, N. Fossati, E. Zaffuto, G. Gandaglia, D. Robesti, D. Cannoletta, M. Menean, D. Cignoli, F. Pellegrino, C.A. Bravi, S. Comana, V. Cucchiara, G. Fallara, P. Dell’Oglio, A. Martini, M. Moschini, A. Rizzo, A. Necchi, A. Salonia, P.I. Karakiewicz, F. Montorsi, F. De Cobelli, A. Briganti
Published 2020-10-01

Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series

by F. Scalvi, A. Stabile, R.J. Karnes, G. Motterle, N. Fossati, G. Gandaglia, F. Barletta, S. Scuderi, V. Cucchiara, L. Nocera, E. Zaffuto, D. Cignoli, G. Rosiello, D. Robesti, D. Cannoletta, E. Zito, M. Menean, E. Mazzone, P. Dell’Oglio, A. Salonia, P.I. Karakiewicz, F. Montorsi, F. De Cobelli, A. Briganti
Published 2020-10-01